Restoring vision in patients with profound optic nerve damage remains one of the most formidable challenges in ophthalmology. While retinal and optic nerve pathologies have traditionally been viewed as the final common pathway for irreversible blindness, advances in cortical neuroprosthetics are now beginning to shift that paradigm. A recent case report, published in Brain Communications, describes a remarkable and unexpected recovery of visual function in a patient with long-standing bilateral non-arteritic anterior ischemic optic neuropathy (NAION) following intracortical microstimulation of the visual cortex.
The patient, a 65-year-old man, had been completely blind for almost four years after sequential bilateral NAION. At enrollment, he had no light perception, bilateral optic atrophy, extinguished pupillary reflexes in one eye, and barely detectable responses in the other. Clinically, it is important to note that this was not a borderline case: visual evoked potentials (VEPs) were essentially absent, and functional vision testing was not possible.
The patient was enrolled in a clinical trial investigating the feasibility of a cortical visual prosthesis using a Utah Electrode Array implanted at the occipital pole, targeting early visual cortex (V1/V2). The goal of the trial was not vision restoration, but the elicitation of artificial percepts (phosphenes) via intracortical electrical stimulation. Yet just two days after implantation, during early stimulation experiments, the unexpected occurred. The patient spontaneously reported perceiving light and motion – not phosphenes, but natural visual sensations. “Perceiving something akin to a shadow,” the patient was able to detect movement in front of him and accurately describe the arm positions of researchers in real time. This marked the first visual experience he had reported since becoming blind almost four years before.
Formal testing confirmed the subjective reports. Performance on the Basic Assessment of Light and Motion (BaLM) rapidly rose above chance and reached ceiling levels within weeks. Over subsequent months, Freiburg visual acuity testing demonstrated a progressive improvement, peaking at a 23-fold gain over baseline binocular acuity. Functionally, this translated into the ability to perceive light and motion, identify large letters and shapes, and navigate more confidently – outcomes that matter deeply to patients’ quality of life.
Crucially, all assessments were performed with the microelectrode implant switched off. The improvements therefore reflected recovery of natural vision rather than prosthetic vision. Even more striking, partial gains persisted long after explantation of the device, with binocular acuity remaining approximately 11 times better than baseline at 18-month follow-up.
Electrophysiology mirrored these behavioral changes. Previously undetectable VEPs became measurable, particularly in the left eye, with increasing amplitudes and evolving latencies over time. Steady-state VEPs showed a similar pattern, suggesting partial re-engagement of the visual pathway at cortical levels.
For ophthalmologists, several points deserve attention. First, spontaneous recovery in NAION typically occurs within weeks to months — not years. Recovery after nearly four years of complete blindness is extraordinarily rare. Second, the patient retained a minimal pupillary response at baseline, raising the possibility that preservation of a small residual substrate may be necessary for recovery. Third, the combination of chronic cortical stimulation and intensive visual training may have reopened a window of adult neuroplasticity, enabling latent visual pathways to regain function.
This single case does not suggest that cortical implants are a treatment for NAION. However, it challenges long-held assumptions about irreversibility of visual loss and highlights the brain – not the eye alone – as a potential therapeutic target. As neuro-ophthalmology, visual rehabilitation, and neurotechnology increasingly converge, such observations may inform future strategies for patients once considered beyond help.
